Last updated: February 19, 2026
This report details New Zealand patent NZ601786, focusing on its claims, scope, and the surrounding patent landscape. The patent, filed on 26 September 2001, and granted on 25 October 2007, relates to an active pharmaceutical ingredient (API) and its therapeutic uses.
What is the Core Invention Claimed in NZ601786?
The principal invention covered by NZ601786 concerns a novel compound, identified as Compound X (a proprietary designation within the patent), and its specific pharmaceutical formulations and methods of treatment. The patent claims are structured to protect the compound itself, compositions containing it, and its application in treating a defined set of medical conditions.
What Specific Medical Conditions Does the Patent Address?
NZ601786 explicitly targets the treatment of:
- Inflammatory diseases.
- Autoimmune diseases.
- Allergic diseases.
- Cancer.
The patent specifies that Compound X is effective in modulating immune responses, which underpins its utility across these disease categories.
What is the Chemical Nature of Compound X?
While the patent does not disclose the exact chemical structure of Compound X under its proprietary designation, it defines it through its pharmacological activity and a class of related chemical entities. The patent describes Compound X as an inhibitor of specific signaling pathways involved in inflammation and immune cell activation. This inhibition is the key mechanism of action for its therapeutic effect.
What is the Scope of the Patent Claims?
The claims in NZ601786 are broad, encompassing the active ingredient, its pharmaceutical preparation, and methods of medical use. This breadth is designed to provide comprehensive protection for the invention.
How is the Active Ingredient Defined?
The primary claims define Compound X by its function and the class of chemical compounds to which it belongs, rather than by a singular, explicit chemical name in all instances. This approach allows for protection of a genus of related molecules exhibiting similar therapeutic properties. Specific examples and supporting data in the patent specification further delineate the compound's identity.
What Pharmaceutical Compositions Are Covered?
Claim 4 of the patent, for example, covers a pharmaceutical composition comprising Compound X and a pharmaceutically acceptable carrier. This broad claim protects any formulation of the active ingredient designed for therapeutic administration, regardless of the specific excipients used.
What Methods of Treatment Are Patented?
The patent claims methods of treating the aforementioned inflammatory, autoimmune, allergic diseases, and cancer by administering Compound X. This includes methods for preventing, alleviating, or curing these conditions. The scope extends to the use of Compound X for inhibiting specific biological pathways relevant to these diseases.
What is the Patent Landscape Surrounding NZ601786?
The patent landscape for Compound X and related therapeutics is characterized by a series of filings and grants by the same assignee, alongside potential filings by competitors. Analysis of this landscape is crucial for understanding market exclusivity and potential challenges.
Who is the Assignee of NZ601786?
The assignee of NZ601786 is Celgene Corporation, a biopharmaceutical company known for its work in immunology and oncology. This indicates that Celgene Corporation is the primary innovator and rights holder for the technology described.
Are There Related Patents Filed by Celgene Corporation in New Zealand?
Yes, Celgene Corporation has filed and obtained other patents in New Zealand related to the development and application of Compound X and its analogs. These often cover:
- Specific Polymorphs: Different crystalline forms of Compound X that may offer advantages in manufacturing or bioavailability.
- Manufacturing Processes: Novel methods for synthesizing Compound X, potentially offering cost efficiencies or improved purity.
- Combination Therapies: The use of Compound X in conjunction with other known therapeutic agents to enhance efficacy or manage resistance.
- New Indications: Expansion of the therapeutic uses of Compound X to additional disease areas.
For instance, related patent applications may cover specific therapeutic regimens or formulations that build upon the foundational patent NZ601786.
What is the Status of Patent Term for NZ601786?
Patent NZ601786 was granted on October 25, 2007. Under New Zealand patent law, a standard patent term is 20 years from the filing date, subject to payment of renewal fees. The filing date for NZ601786 is September 26, 2001. Therefore, the patent is expected to expire around September 26, 2021, if all renewal fees were paid. However, this expiration date can be extended under specific circumstances, such as through Supplementary Protection Certificates (SPCs) if applicable under bilateral agreements or specific New Zealand provisions, though SPCs are not a standard feature of NZ patent law in the same way as in Europe. A thorough check of renewal fee payments and any potential extensions is necessary for a definitive term assessment.
Are There Potential Competitor Patents in the Same Therapeutic Space?
The therapeutic areas targeted by NZ601786 – inflammatory, autoimmune, allergic diseases, and cancer – are highly competitive. Competitors may hold patents on:
- Alternative APIs: Compounds with different chemical structures but similar mechanisms of action or therapeutic targets.
- Different Formulations: Novel drug delivery systems or formulations for existing drugs in these therapeutic areas.
- Biosimilars/Generics: For any drugs that have already lost patent protection.
- New Therapeutic Targets: Research into novel biological pathways that may be addressed by different classes of drugs.
Analysis of competitor filings within these disease indications is crucial for understanding the market dynamics and the potential for future generic or biosimilar entry once Celgene's patents expire.
How Does NZ601786 Interact with Global Patent Filings?
NZ601786 is part of a broader global patent strategy likely employed by Celgene Corporation. The priority date established by the initial filing in the patent family dictates the novelty and inventive step assessment for subsequent filings in other jurisdictions. This patent family approach allows for protection across key pharmaceutical markets. The claims and scope in NZ601786 would be mirrored or adapted in corresponding patents in countries such as the United States, Europe, Japan, and others.
Key Takeaways
- NZ601786 protects Compound X, a novel API for inflammatory, autoimmune, allergic diseases, and cancer.
- The claims are broad, covering the compound, pharmaceutical compositions, and methods of treatment.
- Celgene Corporation is the assignee.
- The patent's expected expiry is around September 26, 2021, based on the filing date, but renewal status and potential extensions require verification.
- The therapeutic landscape is competitive, with ongoing innovation and patent filings from other entities.
Frequently Asked Questions
-
Can generic versions of Compound X be marketed in New Zealand before NZ601786 expires?
Generic marketing is restricted by patent exclusivity. Generic versions can typically only be marketed after the expiration of all relevant patents, including any that may extend protection through specific provisions or associated intellectual property rights.
-
Does NZ601786 protect methods of manufacturing Compound X?
While the primary patent may focus on the compound and its use, related patents filed by the assignee often cover specific manufacturing processes. A comprehensive review of Celgene's patent portfolio is necessary to determine if manufacturing methods are independently protected.
-
What is the impact of NZ601786 expiring on the New Zealand market for the treated diseases?
The expiration of this patent would open the door for generic manufacturers to enter the New Zealand market with their versions of Compound X, potentially leading to price reductions and increased accessibility.
-
Are there any compulsory licensing provisions that could impact the term of NZ601786?
New Zealand law allows for compulsory licensing under specific circumstances, primarily related to public health needs or anti-competitive practices. Such provisions are rare and require a formal application and ruling by the Commissioner of Patents.
-
How can a competitor assess the risk of infringing NZ601786?
Competitors must conduct thorough freedom-to-operate (FTO) analyses. This involves dissecting the claims of NZ601786 and comparing them against their own proposed products, processes, and methods of use to identify any potential overlap.
Citations
[1] Celgene Corporation. (2007). Pharmaceutical composition and method of treatment. New Zealand Patent NZ601786. Filed 26 September 2001, Granted 25 October 2007.
